New U.S. Clinical Trial Explores Cannabis-Based Pain Medication: What Virginia Patients Should Know
Could marijuana-derived medicine provide another option for people struggling with chronic pain? Researchers in the United States are investigating that possibility through a new clinical trial involving a medication developed from compounds found in the marijuana plant.
The experimental medication, known as VER-01, is being studied for its potential to reduce chronic lower back pain. Following promising results in European clinical trials, researchers are now evaluating the medication in American patients to better understand its effectiveness and safety.
For Virginia medical marijuana patients, this research highlights the growing scientific interest in cannabinoids and their possible role in pain management.
Although VER-01 is not currently available through Virginia medical marijuana dispensaries, the study could contribute to future developments in cannabis-based medicine.
Why Is Marijuana Being Studied for Chronic Pain?
Living with chronic pain can make everyday activities difficult. Persistent discomfort may interfere with sleep, mobility, work, exercise, and overall quality of life.
Traditional pain management approaches can include physical therapy, anti-inflammatory medications, injections, and prescription pain relievers. While these treatments help many patients, others continue to experience symptoms despite receiving care.
Researchers are investigating whether medications developed from cannabinoids could provide additional treatment options for certain types of pain.
Cannabinoids interact with the body's endocannabinoid system, which plays a role in regulating pain perception, sleep, and other physiological functions.
However, not all cannabis-based products work the same way. Researchers must study individual formulations to determine their potential benefits, limitations, and safety risks.
VER-01 is one example of this type of research.
What Is VER-01?
VER-01 is an investigational marijuana-derived medication developed by German pharmaceutical company Vertanical.
Unlike conventional marijuana products, VER-01 is manufactured using a standardized cannabis extract. Its controlled formulation allows researchers to evaluate consistent doses during clinical trials.
The medication contains multiple cannabinoids, including:
THC (tetrahydrocannabinol): The primary intoxicating compound in marijuana, which interacts with receptors involved in pain signaling and other bodily functions.
CBD (cannabidiol): A non-intoxicating cannabinoid being investigated for several potential therapeutic applications.
CBG (cannabigerol): A lesser-studied cannabinoid that scientists are examining for possible medical properties.
By combining these compounds in a standardized formulation, researchers hope to better understand how the medication affects chronic pain and whether it could eventually become an approved treatment.
What Is the New U.S. Clinical Trial Investigating?
According to an October 2026 report from NORML, researchers in western New York are studying VER-01 as a potential treatment for chronic lower back pain.
The research involves investigators at Upstate Clinical Research Associates in Williamsville, New York.
The Phase 3 study is designed to compare VER-01 with a placebo in adults experiencing chronic painful lumbosacral radiculopathy, a condition involving pain associated with nerve roots in the lower spine.
Researchers are evaluating several important questions:
Can VER-01 produce meaningful reductions in chronic pain?
Does the medication improve sleep and physical functioning?
What side effects might patients experience?
Is the medication sufficiently safe and effective to support further regulatory review?
The study is particularly focused on patients who have not obtained adequate relief from optimized non-opioid pain treatments or cannot use those treatments because of contraindications or intolerance.
These findings could help researchers determine whether VER-01 may eventually offer another prescription treatment option for certain patients.
What Have Previous VER-01 Studies Found?
VER-01 has already undergone clinical testing in Europe, where researchers reported encouraging findings involving patients with chronic lower back pain.
A Phase 3 study published in Nature Medicine included 820 adults.
Participants receiving VER-01 experienced an average pain reduction of 1.9 points on an 11-point scale, compared with 1.4 points among those receiving a placebo.
Researchers also reported improvements in certain measures of sleep, physical functioning, and quality of life.
Another Phase 3 study published in Pain and Therapy compared VER-01 with opioid medications in 384 adults over six months.
The VER-01 group experienced slightly greater average improvements in pain and sleep, along with fewer reports of constipation.
While these results suggest that VER-01 warrants further investigation, they do not establish that all medical marijuana products provide the same benefits.
The findings apply to a particular investigational medication, and additional research is necessary to determine its long-term effectiveness and safety.
What Does This Research Mean for Virginia Medical Marijuana Patients?
Virginia's medical marijuana program allows eligible patients to access regulated cannabis products following certification from an authorized medical marijuana doctor.
Unlike states that maintain a specific list of qualifying conditions, Virginia allows registered marijuana doctors to determine whether a diagnosed condition or disease may benefit from medical cannabis.
This means chronic pain patients may be eligible for medical marijuana certification when an authorized marijuana doctor determines that marijuana may be appropriate for their condition.
The VER-01 trial is relevant to Virginia patients because it adds to ongoing research into the potential medical applications of cannabinoids.
However, there are important differences between the investigational medication and the marijuana products currently available at Virginia dispensaries.
VER-01 is a standardized pharmaceutical formulation being evaluated under controlled clinical conditions.
Medical marijuana products available through licensed Virginia dispensaries may vary in THC and CBD concentrations, cannabinoid profiles, and methods of administration. These differences can influence how a product affects an individual.
Patients should not assume that results from VER-01 clinical trials will apply to every marijuana product or every type of chronic pain.
Is VER-01 Available at Virginia Medical Marijuana Dispensaries?
No. VER-01 remains an investigational medication and is not available for general use through Virginia medical marijuana dispensaries.
The U.S. Food and Drug Administration granted VER-01 Breakthrough Therapy Designation in May 2026.
This designation is intended to facilitate the development and review of investigational medications that may offer substantial improvements over existing treatments for serious medical conditions.
However, Breakthrough Therapy Designation is not the same as FDA approval. VER-01 must still undergo additional evaluation and meet the FDA's requirements before it can be approved for general medical use.
For now, Virginia patients interested in medical marijuana must follow the state's existing certification process and obtain products through licensed medical cannabis dispensaries.
How to Get a Virginia Medical Marijuana Card
Virginia's medical marijuana program differs from programs in many other states.
Patients do not need to obtain a separate state-issued medical marijuana identification card. Instead, eligible patients receive a written medical marijuana certification from an authorized marijuana doctor.
The process involves:
Schedule a medical marijuana evaluation. Meet with an eligible Virginia healthcare practitioner to discuss your medical history, symptoms, and treatment goals.
Complete your medical assessment. The practitioner determines whether you have a diagnosed condition that may benefit from medical cannabis.
Receive your written certification. If approved, the practitioner issues an electronic or printed certification through Virginia's medical cannabis system.
Visit a licensed Virginia dispensary. Present your valid certification and government-issued identification to purchase authorized medical cannabis products.
Virginia permits medical marijuana certifications through telemedicine when the evaluation meets applicable legal and professional requirements, including real-time interactive audiovisual communication.
Eligible certifying practitioners include licensed physicians, physician assistants, and qualifying advanced practice registered nurses.
For more information, visit the Virginia Cannabis Control Authority.
Can You Qualify for Medical Marijuana in Virginia for Chronic Pain?
Yes, patients experiencing chronic pain may qualify for medical marijuana certification in Virginia.
Unlike states with narrowly defined qualifying-condition lists, Virginia allows authorized marijuana doctors to use their professional judgment when determining whether a patient's diagnosed condition may benefit from marijuana.
This approach provides flexibility for patients experiencing different medical conditions.
However, certification is not automatic. A practitioner must evaluate the patient's individual circumstances and determine whether medical marijuana is appropriate.
Patients should be prepared to discuss their medical history, current medications, previous treatments, and any potential risks associated with cannabis use.
What Could This Trial Mean for the Future of Pain Management?
The VER-01 clinical trial represents another step toward understanding how marijuana-derived compounds may be used in modern medicine.
By studying standardized formulations, researchers can better evaluate whether specific cannabinoids provide measurable benefits for particular medical conditions.
For Virginia patients, this research may help inform future conversations about cannabis-based treatments and chronic pain management.
However, more clinical evidence is needed before VER-01 can become an FDA-approved medication.
Patients should continue working with qualified healthcare professionals to understand their available treatment options and make informed decisions about their care.
Comments